Epidemiological and clinical characteristics of survivors of SARS-COV-2 infection: A descriptive study. / Características epidemiológicas y clínicas de sobrevivientes a infección por SARS-CoV-2: estudio descriptivo.

Introduction: In March 2020, the World Health Organization (WHO) declared a pandemic for coronavirus 19. Typical symptoms were fever, cough, asthenia, dyspnea, and muscle pain. Pulmonary and central nervous system compromise presented challenging characteristics for healthcare physicians. The objectives of this study were to identify epidemiological and clinical characteristics of SARS-COV-2 infection survivors in a region of Argentina and to determine differences between gender, age groups, year of infection, and evolution time since diagnosis. Methods: A descriptive and analytical cross-sectional observational study was carried out. A self-administered questionnaire was applied, which was available between August and December 2021. Results: Among 1868 individuals included, the mean age was 39.4 ± 13.9 years, and 72.8% were female. Arterial hypertension was the most frequent comorbidity (11.7%). The majority were outpatients (81.9%). The most frequent presentation symptoms at all ages were asthenia (83.7%), fever (54.9%), headache (60.8%), anosmia (64.8%), ageusia (53.2%), cough (54.4%) and myalgias (53.7%). For the 18 to 29 years old age group, the most prevalent presentation symptoms were: headache (69.4%), anosmia (69.1%), ageusia (60.2%), odynophagia (45%), and rhinitis/nasal congestion (46.9%). In the 30 to 64 years old age group, there was a higher prevalence of myalgias (55.8%), arthralgias (41%), and concentration/memory disorder (28.3%). Male showed higher prevalence of fever (64.9% versus 51.1%; p < 0.001) and pneumonia (23.5% versus 13.4%; p < 0.001). After 12 weeks from diagnosis, 38.1% of patients persisted with asthenia, 23.6% with anosmia/dysosmia, and 21.2% with concentration/memory disorders. Conclusions: Systemic symptoms were common to all age groups with coronavirus 19 disease; however, younger, and intermediate age groups presented a higher prevalence of central nervous system symptoms such as anosmia and cognitive disorders, respectively. Symptoms beyond 12 weeks of diagnosis reached slightly more than 10% of the participants.

Introducción: En marzo de 2020 la enfermedad por coronavirus 19 fue declarada pandemia por la Organización Mundial de la Salud. Los síntomas más comunes fueron fiebre, tos, astenia, disnea y dolor muscular. Los compromisos pulmonar y del sistema nervioso central presentaron características desafiantes para los médicos asistenciales. Los objetivos del estudio fueron conocer las características epidemiológicas y clínicas de sobrevivientes a infección por SARS-CoV-2 en una región de Argentina, y determinar las diferencias entre género, grupos etarias, año de contagio, tiempo de evolución desde el diagnóstico. Métodos: Se realizó un estudio observacional descriptivo y analítico de corte transversal. Se aplicó un cuestionario auto administrado, que estuvo disponible entre agosto y diciembre de 2021. Resultados: La media de edad fue de 39,4 ± 13,9 años, el 72,8% fueron mujeres. La comorbilidad más frecuente fue hipertensión arterial (11,7%). La mayoría de los pacientes fueron ambulatorios (81,9%). Los síntomas de presentación más frecuentes a cualquier edad, fueron astenia (83,7%), fiebre (54,9%), cefalea (60,8%), anosmia (64,8%), ageusia (53,2%), tos (54,4%) y mialgias (53,7%). Para el grupo de 18 a 29 años los síntomas de presentación más prevalentes fueron cefalea (69,4%), anosmia 69,1%), ageusia (60,2%), odinofagia (45%) y rinitis/congestión nasal (46,9%). En el grupo de 30 a 64 años se observó mayor prevalencia de mialgias (55,8%), artralgias (41%), falta de concentración/memoria (28,3%). Los hombres mostraron más prevalencia de fiebre (64,9% versus 51,1%; p < 0,001) y neumonía (23,5% versus 13,4%; p < 0,001). Luego de las 12 semanas del diagnóstico 38,1% de los pacientes persistían con astenia, 23,6% con anosmia/disosmia y 21,2% con trastornos de concentración/memoria. Conclusiones: La enfermedad por coronavirus 19 presenta un patrón de síntomas sistémicos común a todos los grupos etarios. No obstante, los grupos más jóvenes presentan más prevalencia de síntomas de afección del sistema nervioso central como la anosmia y los grupos intermedios, mayor prevalencia de trastornos cognitivos. Los síntomas más allá de las 12 semanas del diagnóstico alcanzaron a algo más del 10% de los participantes.

Características epidemiológicas y clínicas de sobrevivientes a infección por SARS-CoV-2: estudio descriptivo / Epidemiological and clinical characteristics of survivors of SARS-COV-2 infection: A descriptive study

Introducción En marzo de 2020 la enfermedad por coronavirus 19 fue declarada pandemia por la Organización Mundial de la Salud. Los síntomas más comunes fueron fiebre, tos, astenia, disnea y dolor muscular. Los compromisos pulmonar y del sistema nervioso central presentaron características desafiantes para los médicos asistenciales. Los objetivos del estudio fueron conocer las características epidemiológicas y clínicas de sobrevivientes a infección por SARS-CoV-2 en una región de Argentina, y determinar las diferencias entre género, grupos etarias, año de contagio, tiempo de evolución desde el diagnóstico. Métodos Se realizó un estudio observacional descriptivo y analítico de corte transversal. Se aplicó un cuestionario auto administrado, que estuvo disponible entre agosto y diciembre de 2021. Resultados La media de edad fue de 39,4 ± 13,9 años, el 72,8% fueron mujeres. La comorbilidad más frecuente fue hipertensión arterial (11,7%). La mayoría de los pacientes fueron ambulatorios (81,9%). Los síntomas de presentación más frecuentes a cualquier edad, fueron astenia (83,7%), fiebre (54,9%), cefalea (60,8%), anosmia (64,8%), ageusia (53,2%), tos (54,4%) y mialgias (53,7%). Para el grupo de 18 a 29 años los síntomas de presentación más prevalentes fueron cefalea (69,4%), anosmia 69,1%), ageusia (60,2%), odinofagia (45%) y rinitis/congestión nasal (46,9%). En el grupo de 30 a 64 años se observó mayor prevalencia de mialgias (55,8%), artralgias (41%), falta de concentración/memoria (28,3%). Los hombres mostraron más prevalencia de fiebre (64,9% versus 51,1%; p < 0,001) y neumonía (23,5% versus 13,4%; p < 0,001). Luego de las 12 semanas del diagnóstico 38,1% de los pacientes persistían con astenia, 23,6% con anosmia/disosmia y 21,2% con trastornos de concentración/memoria. Conclusiones La enfermedad por coronavirus 19 presenta un patrón de síntomas sistémicos común a todos los grupos etarios. No obstante, los grupos más jóvenes presentan más prevalencia de síntomas de afección del sistema nervioso central como la anosmia y los grupos intermedios, mayor prevalencia de trastornos cognitivos. Los síntomas más allá de las 12 semanas del diagnóstico alcanzaron a algo más del 10% de los participantes.

Introduction In March 2020, the World Health Organization (WHO) declared a pandemic for coronavirus 19. Typical symptoms were fever, cough, asthenia, dyspnea, and muscle pain. Pulmonary and central nervous system compromise presented challenging characteristics for healthcare physicians. The objectives of this study were to identify epidemiological and clinical characteristics of SARS-COV-2 infection survivors in a region of Argentina and to determine differences between gender, age groups, year of infection, and evolution time since diagnosis. Methods A descriptive and analytical cross-sectional observational study was carried out. A self-administered questionnaire was applied, which was available between August and December 2021. Results Among 1868 individuals included, the mean age was 39.4 ± 13.9 years, and 72.8% were female. Arterial hypertension was the most frequent comorbidity (11.7%). The majority were outpatients (81.9%). The most frequent presentation symptoms at all ages were asthenia (83.7%), fever (54.9%), headache (60.8%), anosmia (64.8%), ageusia (53.2%), cough (54.4%) and myalgias (53.7%). For the 18 to 29 years old age group, the most prevalent presentation symptoms were: headache (69.4%), anosmia (69.1%), ageusia (60.2%), odynophagia (45%), and rhinitis/nasal congestion (46.9%). In the 30 to 64 years old age group, there was a higher prevalence of myalgias (55.8%), arthralgias (41%), and concentration/memory disorder (28.3%). Male showed higher prevalence of fever (64.9% versus 51.1%; p < 0.001) and pneumonia (23.5% versus 13.4%; p < 0.001). After 12 weeks from diagnosis, 38.1% of patients persisted with asthenia, 23.6% with anosmia/dysosmia, and 21.2% with concentration/memory disorders. Conclusions Systemic symptoms were common to all age groups with coronavirus 19 disease; however, younger, and intermediate age groups presented a higher prevalence of central nervous system symptoms such as anosmia and cognitive disorders, respectively. Symptoms beyond 12 weeks of diagnosis reached slightly more than 10% of the participants.

Complicaciones tromboembólicas de los pacientes internados por COVID-19 / Thromboembolic complications in patients with COVID-19

Resumen La enfermedad producida por el COVID-19 ha generado un problema sanitario mundial sin precedentes. La infección se considera como un potencial factor de riesgo para desarrollar complica ciones tromboembólicas, principalmente, embolia pulmonar, infarto de miocardio y accidente cerebrovascular. El objetivo de este trabajo fue describirlas en los pacientes internados por COVID-19 y su evolución. Se realizó un estudio observacional unicéntrico prospectivo que comparó las características basales, factores de riesgo, tasa de eventos tromboembólicos, estadía y mortalidad hospitalaria entre los pacientes que se internaron en cuidados intensivos o sala general. Se incluyeron 1125 pacientes, 124 internados en unidad cuidados intensivos y 1001 internados en sala general de internación. La edad promedio fue de 46 ± 18 años, con 585 (52%) de sexo femenino. La tasa global de eventos tromboembólicos fue de 4.4%, siendo significativamente mayor en los pacientes de UCI (29% vs. 1.4%; p < 0.001) a pesar del elevado uso de heparina profiláctica (91.1% vs. 84.9%; p < 0.1), comparados con los internados en SGI. Los factores predictores independientes de desarrollo de eventos tromboembólicos fueron: la edad, el dímero D y la creatinina. La mortalidad global fue 4.3%, siendo significativamente mayor en los pacientes de cuidados intensivos sobre los de sala general de internación (29% vs. 1.3%; p < 0.001). Los pacientes que requieren internación por COVID-19 presentan elevada tasa de eventos tromboembólicos a pesar del uso de tromboprofilaxis con heparina, generando un impacto pronóstico negativo sobre la supervivencia de aquellos internados en cuidados intensivos.

Abstract Coronavirus disease-19 has emerged as a devastating global public health crisis. An increased frequency of arterial and venous thrombosis was observed in COVID-19 infection. The objective of this study was to describe the thromboembolic complications of patients hospitalized for COVID-19 and their evolution. A prospective single-center study was conducted that compared the characteristics, risk factors, thromboembolic event rate, hospital stay and mortal ity among patients admitted to intensive care or general ward. The mean age of population was 46 ± 18 years, and 52% were female. The global rate of thromboembolic events was 4.4%, significantly higher in intensive unit patients (29% vs 1.4%; p < 0.001) despite the high use of prophylactic heparin (91.1% vs. 84.9%; p < 0.1). The independent predictive factors for the development of thromboembolic events were: age, D-dimer and creatinine. Of the patients admitted to intensive care, 45.1% required mechanical ventilation. Overall mortality was 4.3%, significantly higher in intensive care patients than in the general hospital ward (29% vs. 1.3%; p < 0.0001). Pa tients requiring hospitalization due to infection secondary to COVID-19 have a high rate of thromboembolic events despite the use of thromboprophylaxis with heparin, generating a negative prognostic impact on the survival of patients admitted to intensive care.

[Thromboembolic complications in patients with COVID-19]. / Complicaciones tromboembólicas de los pacientes internados por COVID-19.

Coronavirus disease-19 has emerged as a devastating global public health crisis. An increased frequency of arterial and venous thrombosis was observed in COVID-19 infection. The objective of this study was to describe the thromboembolic complications of patients hospitalized for COVID-19 and their evolution. A prospective single-center study was conducted that compared the characteristics, risk factors, thromboembolic event rate, hospital stay and mortality among patients admitted to intensive care or general ward. The mean age of population was 46 ± 18 years, and 52% were female. The global rate of thromboembolic events was 4.4%, significantly higher in intensive unit patients (29% vs 1.4%; p < 0.001) despite the high use of prophylactic heparin (91.1% vs. 84.9%; p < 0.1). The independent predictive factors for the development of thromboembolic events were: age, D-dimer and creatinine. Of the patients admitted to intensive care, 45.1% required mechanical ventilation. Overall mortality was 4.3%, significantly higher in intensive care patients than in the general hospital ward (29% vs. 1.3%; p < 0.0001). Patients requiring hospitalization due to infection secondary to COVID-19 have a high rate of thromboembolic events despite the use of thromboprophylaxis with heparin, generating a negative prognostic impact on the survival of patients admitted to intensive care.

La enfermedad producida por el COVID-19 ha generado un problema sanitario mundial sin precedentes. La infección se considera como un potencial factor de riesgo para desarrollar complicaciones tromboembólicas, principalmente, embolia pulmonar, infarto de miocardio y accidente cerebrovascular. El objetivo de este trabajo fue describirlas en los pacientes internados por COVID-19 y su evolución. Se realizó un estudio observacional unicéntrico prospectivo que comparó las características basales, factores de riesgo, tasa de eventos tromboembólicos, estadía y mortalidad hospitalaria entre los pacientes que se internaron en cuidados intensivos o sala general. Se incluyeron 1125 pacientes, 124 internados en unidad cuidados intensivos y 1001 internados en sala general de internación. La edad promedio fue de 46 ± 18 años, con 585 (52%) de sexo femenino. La tasa global de eventos tromboembólicos fue de 4.4%, siendo significativamente mayor en los pacientes de UCI (29% vs. 1.4%; p < 0.001) a pesar del elevado uso de heparina profiláctica (91.1% vs. 84.9%; p < 0.1), comparados con los internados en SGI. Los factores predictores independientes de desarrollo de eventos tromboembólicos fueron: la edad, el dímero D y la creatinina. La mortalidad global fue 4.3%, siendo significativamente mayor en los pacientes de cuidados intensivos sobre los de sala general de internación (29% vs. 1.3%; p < 0.001). Los pacientes que requieren internación por COVID-19 presentan elevada tasa de eventos tromboembólicos a pesar del uso de tromboprofilaxis con heparina, generando un impacto pronóstico negativo sobre la supervivencia de aquellos internados en cuidados intensivos.

Predictability of adverse outcomes in hypertensive disorders of pregnancy: a multicenter prospective cohort study.

OBJECTIVES: To explore variables associated with adverse maternal/fetal/neonatal outcomes among pregnant/postpartum patients admitted to ICU for hypertensive disorders of pregnancy (HDP). METHODS: Multicenter, prospective, national cohort study. RESULTS: Variables independently associated with maternal/fetal/neonatal mortality among 172 patients were as follows: Acute Physiology and Chronic Health Evaluation-II (APACHE-II)(OR1.20[1.06-1.35]), gestational age (OR0.698[0.59-0.82]) and aspartate aminotransferase (AST)(OR1.004[1.001-1.006]). Positive likelihood ratio for headache, epigastric pain, and visual disturbances to predict composite adverse outcomes were 1.23(1.16-1.30), 0.76(0.59-1.02), and 1.1(0.98-1.2), respectively. CONCLUSIONS: Maternal/fetal mortality due to HDP was independently associated with severity of illness on admission, gestational age, and elevated AST. Accuracy of clinical symptoms to predict composite adverse outcomes was low.

High-Flow Oxygen Therapy Application in Chronic Obstructive Pulmonary Disease Patients With Acute Hypercapnic Respiratory Failure: A Multicenter Study.

OBJECTIVES: To evaluate the effect of high-flow oxygen implementation on the respiratory rate as a first-line ventilation support in chronic obstructive pulmonary disease patients with acute hypercapnic respiratory failure. DESIGN: Multicenter, prospective, analytic observational case series study. SETTING: Five ICUs in Argentina, between August 2018 and September 2019. PATIENTS: Patients greater than or equal to 18 years old with moderate to very severe chronic obstructive pulmonary disease, who had been admitted to the ICU with a diagnosis of hypercapnic acute respiratory failure, were entered in the study. INTERVENTIONS: High-flow oxygen therapy through nasal cannula delivered using high-velocity nasal insufflation. MEASUREMENTS AND MAIN RESULTS: Forty patients were studied, 62.5% severe chronic obstructive pulmonary disease. After the first hour of high-flow nasal cannula implementation, there was a significant decrease of respiratory rate compared with baseline values, with a 27% decline (29 vs 21 breaths/min; p < 0.001). Furthermore, a significant reduction of Paco2 (57 vs 52 mm Hg [7.6 vs 6.9 kPa]; p < 0.001) was observed. The high-flow nasal cannula application failed in 18% patients. In this group, the respiratory rate, pH, and Paco2 showed no significant change during the first hour in these patients. CONCLUSIONS: High-flow oxygen therapy through nasal cannula delivered using high-velocity nasal insufflation was an effective tool for reducing respiratory rate in these chronic obstructive pulmonary disease patients with acute hypercapnic respiratory failure. Early determination and subsequent monitoring of clinical and blood gas parameters may help predict the outcome.

Effects of High-Flow Nasal Cannula on End-Expiratory Lung Impedance in Semi-Seated Healthy Subjects.

BACKGROUND: High-flow nasal cannula (HFNC) enables delivery of humidified gas at high flow while controlling the FIO2 . Although its use is growing in patients with acute respiratory failure, little is known about the impact of HFNC on lung volume. Therefore, we aimed to assess lung volume changes in healthy subjects at different flows and positions. METHODS: This was a prospective physiological study performed in 16 healthy subjects. The changes in lung volumes were assessed by measuring end-expiratory lung impedance by using electrical impedance tomography. All the subjects successively breathed during 5 min in these following conditions: while in a supine position without HFNC (T0) and 3 measurements in a semi-seated position at 45° without HFNC (T1), and with HFNC at a flow of 30 L/min (T2), and 50 L/min (T3). RESULTS: Compared with the supine position, the values of end-expiratory lung impedance significantly increased with the subjects in a semi-seated position. End-expiratory lung impedance significantly increased after HFNC initiation in subjects in a semi-seated position and further increased by increasing flow at 50 L/min. When taking the end-expiratory lung impedance measurement in subjects in a semi-seated position (T1) as reference, the differences among the medians of global end-expiratory lung impedance were statistically significant (P < .001), which amounted to 1.05 units in T1; 1.12 units in T2; and 1.44 units in T3 (P < .05 for all comparisons, Wilcoxon test). The breathing frequency did not differ between the supine and semi-seated position (T0 and T1) but significantly decreased after initiation of HFNC and further decreased at high flow. T0 and T1 were not different (P = .13); whereas there was a statistically significant difference among T1, T2, and T3 (P < .05, post hoc test with Bonferroni correction). CONCLUSIONS: In healthy subjects, the semi-seated position and the use of HFNC increased end-expiratory lung impedance globally. These changes were accompanied by a significant decrease in the breathing frequency.

Evaluation of an active humidification system for inspired gas.

OBJECTIVES: The effectiveness of the active humidification systems (AHS) in patients already weaned from mechanical ventilation and with an artificial airway has not been very well described. The objective of this study was to evaluate the performance of an AHS in chronically tracheostomized and spontaneously breathing patients. METHODS: Measurements were quantified at three levels of temperature (T°) of the AHS: level I, low; level II, middle; and level III, high and at different flow levels (20 to 60 L/minute). Statistical analysis of repeated measurements was performed using analysis of variance and significance was set at a P<0.05. RESULTS: While the lowest temperature setting (level I) did not condition gas to the minimum recommended values for any of the flows that were used, the medium temperature setting (level II) only conditioned gas with flows of 20 and 30 L/minute. Finally, at the highest temperature setting (level III), every flow reached the minimum absolute humidity (AH) recommended of 30 mg/L. CONCLUSION: According to our results, to obtain appropiate relative humidity, AH and T° of gas one should have a device that maintains water T° at least at 53℃ for flows between 20 and 30 L/m, or at T° of 61℃ at any flow rate.

Hypertensive disease of pregnancy in the ICU: a multicenter study.

OBJECTIVE: To describe characteristics, outcomes and clinical presentations for hypertensive disease of pregnancy (HDP) in patients admitted to three ICUs in Argentina. METHODS: Case-series multicenter study. RESULTS: There were 184 patients with HDP. Mean age 26 ± 8; 90% did not present comorbidity; APACHEII 9[6-14]; SOFA24 2[1-4]; ICU-LOS 3[2-6] days and hospital-LOS 8[5-12] days. Gestational age 34 ± 5 weeks; 46% (85) nulliparous and 71% received routine prenatal care. Maternal mortality 3.3% (6) - 50% attributed to intracranial hemorrhage (ICH). Neonatal mortality 13.6%. Diagnostic categories: eclampsia (64; 35%), severe preeclampsia (60; 32.6%), HELLP (33; 17.9%), eclampsia-HELLP (18; 9.8%) and other (chronic/gestational-hypertension) (9: 4.7%). Severe hypertension in 46%, multiple organ dysfunction in 23%, acute respiratory distress in 8.7% and acute renal failure in 8%. Variables independently associated with eclampsia: maternal age (OR 1.07 [1.02-1.13], gestational age (OR 1.14 [1.04-1.24]) and nulliparity (OR 2.40 [1.19-4.85]). CONCLUSIONS: Although patients were young and the majority received appropriate prenatal care, they spent considerable time in hospital and presented severe morbidity. Maternal mortality was 3.3% and in half of these cases it was attributed to ICH. Eclampsia and severe preeclampsia represented two thirds of the diagnostic categories. Variables independently associated with eclampsia were maternal and gestational ages and nulliparity.

Health insurance status and outcomes of critically ill obstetric patients: a prospective cohort study in Argentina.

PURPOSE: In Argentina, uninsured patients receive public health care, and the insured receive private health care. Our aim was to compare different outcomes between critically ill obstetric patients from both sectors. METHODS: This is a prospective cohort, including pregnant/postpartum patients requiring admission to 1 intensive care unit in the public sector (uninsured) and 1 in the private (insured) from January 1, 2008, to September 30, 2011. RESULTS: A total of 151 patients were included in the study. In uninsured (n = 63) vs insured (n = 88) patients, Acute Physiology and Chronic Evaluation II (APACHE II) and Sequential Organ Failure Assessment scores were 11 ± 6.5 vs 8 ± 4 and 3 (2-7) vs 1 (0-2), respectively, and 84% vs 100% received prenatal care (P = .001 for all). Multiple organ dysfunction syndrome (MODS) was present in 32 (54%) uninsured vs 9 (10%) insured patients (P = .001), and acute respiratory distress syndrome developed in 18 (30.5%) of 59 vs 2(2%) of 88 (P = .001). Neonatal survival was 80% vs 96% (P = .003). Variables independently associated with the development of MODS were APACHE II (odds ratio, 1.30 [1.13-1.49]), referral from another hospital (odds ratio, 11.43 [1.86-70.20]), lack of health insurance (odds ratio 6.75 [2.17-20.09]), and shock (odds ratio 4.82 [1.54-15.06]). Three patients died, all uninsured. CONCLUSIONS: Uninsured critically ill obstetric patients (public sector) were more severely ill on admission and experienced worse outcomes than insured patients (private sector). Variables independently associated with MODS were APACHE II, shock, referral from another hospital, and lack of insurance.

[Clinical, epidemiological and immunological study of patients coinfected with HIV and HTLV-1]. / Estudio epidemiológico, clinico e inmunológico de pacientes coinfectados con HIV y HTLV-1.

We studied the prevalence of antibodies against HTLV-1 among every HIV-infected outpatients assisted in our hospital between January 1st 2000 and June 30th 2003. We reviewed the epidemiological data, clinical findings, viral load and CD4 cells-count, comparing coinfected with non HTLV-1 coinfected. We found a prevalence of HTLV-1 infection of 8.1% (23/282); 8.5% (12/141) in men and 7.8% (11/141) in women [[OR=0.91 (0.36

Estudio epidemiologico, clinico e inmunologico de pacientes coinfectados con HIV y HTLV-1 / Clinical, epidemiological and immunological study of patients coinfected with HIV and HTLV-1

Se efectuó un estudio prospectivo parcial de seroprevalencia de HTLV-1 en todos los pacientes infectados con HIV seguidos en el consultorio externo de infectología de nuestro hospital entre el 1 de enero de 2000 y el 30 de junio de 2003. Se analizaron retrospectivamente las características clínicas, carga viral de HIV (CV) y recuento de células CD4, comparando a la población de pacientes coinfectados y no coinfectados. Hallamos una seroprevalencia de HTLV-1 de 8.1% (23/282); 8.5% (12/141) entre hombres y 7.8% (11/141) entre mujeres [OR=0.91 (0.36 < OR < 2.3) p=0.8]; 12.4% (16/129) entre consumidores de drogas y 4.6% (7/152) entre quienes no consumían drogas [OR=2.93 (1.09 < OR < 8.17) p=0.03]; 20.8% (16/77) entre adictos a drogas intravenosas (DIV) y 3.4% (7/205) entre los no-DIV [OR=7.42 (2.71 < OR < 20.9) p=0.000006]. Noventa y seis pacientes (96/282) habían tenido enfermedad marcadora (EM) de SIDA, el tipo de EM no difirió entre los coinfectados y no coinfectados. Ningún paciente desarrolló enfermedad vinculable con HTLV-1. El CD4 promedio en los pacientes portadores de HTLV-1 con antecedentes de EM y vírgenes de antirretrovirales (n=7) fue 211 células/ml, y 87.9 células/ml entre los no coinfectados (n=55) [test-t=2.82; p=0.006]. La CV de los pacientes coinfectados fue similar a la de los no coinfectados. Hallamos una alta prevalencia de infección por HTLV-1 entre los pacientes portadores de HIV (mayor aún entre los usuarios de drogas). El recuento de CD4 en los pacientes que presentaron EM fue superior en los coinfectados con HTLV-1 que en los no coinfectados, lo cual podría evidenciar algún grado de disfunción de dichas células.

Estudio epidemiologico, clinico e inmunologico de pacientes coinfectados con HIV y HTLV-1 / Clinical, epidemiological and immunological study of patients coinfected with HIV and HTLV-1

Se efectuó un estudio prospectivo parcial de seroprevalencia de HTLV-1 en todos los pacientes infectados con HIV seguidos en el consultorio externo de infectología de nuestro hospital entre el 1 de enero de 2000 y el 30 de junio de 2003. Se analizaron retrospectivamente las características clínicas, carga viral de HIV (CV) y recuento de células CD4, comparando a la población de pacientes coinfectados y no coinfectados. Hallamos una seroprevalencia de HTLV-1 de 8.1% (23/282); 8.5% (12/141) entre hombres y 7.8% (11/141) entre mujeres [OR=0.91 (0.36 < OR < 2.3) p=0.8]; 12.4% (16/129) entre consumidores de drogas y 4.6% (7/152) entre quienes no consumían drogas [OR=2.93 (1.09 < OR < 8.17) p=0.03]; 20.8% (16/77) entre adictos a drogas intravenosas (DIV) y 3.4% (7/205) entre los no-DIV [OR=7.42 (2.71 < OR < 20.9) p=0.000006]. Noventa y seis pacientes (96/282) habían tenido enfermedad marcadora (EM) de SIDA, el tipo de EM no difirió entre los coinfectados y no coinfectados. Ningún paciente desarrolló enfermedad vinculable con HTLV-1. El CD4 promedio en los pacientes portadores de HTLV-1 con antecedentes de EM y vírgenes de antirretrovirales (n=7) fue 211 células/ml, y 87.9 células/ml entre los no coinfectados (n=55) [test-t=2.82; p=0.006]. La CV de los pacientes coinfectados fue similar a la de los no coinfectados. Hallamos una alta prevalencia de infección por HTLV-1 entre los pacientes portadores de HIV (mayor aún entre los usuarios de drogas). El recuento de CD4 en los pacientes que presentaron EM fue superior en los coinfectados con HTLV-1 que en los no coinfectados, lo cual podría evidenciar algún grado de disfunción de dichas células. (AU)

Estudio epidemiológico, clinico e inmunológico de pacientes coinfectados con HIV y HTLV-1. / [Clinical, epidemiological and immunological study of patients coinfected with HIV and HTLV-1]

We studied the prevalence of antibodies against HTLV-1 among every HIV-infected outpatients assisted in our hospital between January 1st 2000 and June 30th 2003. We reviewed the epidemiological data, clinical findings, viral load and CD4 cells-count, comparing coinfected with non HTLV-1 coinfected. We found a prevalence of HTLV-1 infection of 8.1

(23/282); 8.5

(12/141) in men and 7.8

(11/141) in women [[OR=0.91 (0.36

(16/129) among patients users of illicit drugs and 4.6

(7/152) among non-users [OR=2.93 (1.09

(16/77) in injecting drugs users (IDU) and 3.4

(7/205) in non-IDU patients [p=0.000006 OR=7.42 (2.71